Malaria: therapeutic implications of melatonin

Area of Science:

• Parasitology
• Chronobiology
• Pharmacology

Background:

• Malaria affects over 300 million people annually, causing over one million deaths, primarily in children.
• Plasmodium falciparum and Plasmodium chabaudi parasite maturation may be synchronized by circadian changes in melatonin.
• Melatonin signaling pathways involve specific receptors, phospholipase-C activation, and intracellular calcium (Ca2+) increases.

Purpose of the Study:

• To investigate the role of melatonin in the synchronous maturation of malaria parasites.
• To explore the potential of targeting melatonin pathways for malaria treatment.
• To examine the dual effects of melatonin in malaria, including its potential protective role against oxidative stress.

Main Methods:

• In vitro studies on Plasmodium falciparum and Plasmodium chabaudi.
• Melatonin receptor activation and Ca2+ signaling pathway analysis.
• Pinealectomy and administration of melatonin receptor antagonist (luzindole) in experimental models.

Main Results:

• In vitro, melatonin stimulates P. falciparum growth and development via receptor activation and Ca2+ signaling, promoting parasite transition to the schizont stage.
• Blocking melatonin receptors or pinealectomy desynchronizes the parasitic cell cycle.
• High-dose melatonin treatment demonstrated benefits in inhibiting apoptosis and reducing liver damage caused by oxidative stress in malaria.

Conclusions:

• Melatonin antagonists represent a potential novel therapeutic strategy for malaria control by disrupting parasite synchronization.
• The complex role of melatonin in malaria suggests a potential dual therapeutic approach combining antagonists with high-dose melatonin to combat parasite proliferation and oxidative damage.